EA201892475A1 - Оксабороловые сложные эфиры, их применение - Google Patents

Оксабороловые сложные эфиры, их применение

Info

Publication number
EA201892475A1
EA201892475A1 EA201892475A EA201892475A EA201892475A1 EA 201892475 A1 EA201892475 A1 EA 201892475A1 EA 201892475 A EA201892475 A EA 201892475A EA 201892475 A EA201892475 A EA 201892475A EA 201892475 A1 EA201892475 A1 EA 201892475A1
Authority
EA
Eurasian Patent Office
Prior art keywords
oxaborolic
application
complex ethers
ethers
complex
Prior art date
Application number
EA201892475A
Other languages
English (en)
Other versions
EA036661B1 (ru
Inventor
Цутому АКАМА
Дэвид Скотт Картер
Джейсон С. Холлэдэй
Роберт Т. Джейкобс
Ян Лю
Джейкоб Дж. Плэттнер
Юн-Кан Чзан
Майкл Джон Уитти
Original Assignee
Анакор Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Анакор Фармасьютикалс, Инк. filed Critical Анакор Фармасьютикалс, Инк.
Publication of EA201892475A1 publication Critical patent/EA201892475A1/ru
Publication of EA036661B1 publication Critical patent/EA036661B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/14Ectoparasiticides, e.g. scabicides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02Boron compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02Boron compounds
    • C07F5/027Organoboranes and organoborohydrides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)

Abstract

В настоящем изобретении предложены оксабороловые сложноэфирные соединения и их композиции, которые являются полезными в лечении заболеваний, связанных с паразитами, таких как болезнь Шагаса и африканский трипаносомоз животных.
EA201892475A 2016-05-12 2017-05-01 Оксабороловые сложные эфиры и способ лечения паразитической инфекции EA036661B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662335565P 2016-05-12 2016-05-12

Publications (2)

Publication Number Publication Date
EA201892475A1 true EA201892475A1 (ru) 2019-04-30
EA036661B1 EA036661B1 (ru) 2020-12-04

Family

ID=58699201

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201892475A EA036661B1 (ru) 2016-05-12 2017-05-01 Оксабороловые сложные эфиры и способ лечения паразитической инфекции
EA201892203A EA034415B1 (ru) 2016-05-12 2017-05-01 Оксабороловые сложные эфиры и их применения

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201892203A EA034415B1 (ru) 2016-05-12 2017-05-01 Оксабороловые сложные эфиры и их применения

Country Status (31)

Country Link
US (4) US10562921B2 (ru)
EP (2) EP3455227A1 (ru)
JP (2) JP6715957B2 (ru)
KR (2) KR102243775B1 (ru)
CN (2) CN109503637B (ru)
AR (2) AR108450A1 (ru)
AU (2) AU2017263785B2 (ru)
BR (2) BR122018076188A2 (ru)
CA (1) CA3023490C (ru)
CL (2) CL2018003187A1 (ru)
CO (1) CO2018012077A2 (ru)
CR (2) CR20180502A (ru)
DK (1) DK3578562T3 (ru)
EA (2) EA036661B1 (ru)
EC (2) ECSP18091065A (ru)
ES (1) ES2882782T3 (ru)
HK (1) HK1258717A1 (ru)
HU (1) HUE056320T2 (ru)
IL (2) IL262453A (ru)
MA (1) MA44968A (ru)
MX (2) MX2018013743A (ru)
NI (2) NI201801171A (ru)
NZ (1) NZ746906A (ru)
PE (2) PE20191077A1 (ru)
PT (1) PT3578562T (ru)
SG (1) SG11201809237RA (ru)
TN (2) TN2018000351A1 (ru)
TW (1) TWI629279B (ru)
UA (2) UA120999C2 (ru)
UY (2) UY37236A (ru)
WO (1) WO2017195069A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
WO2017155879A1 (en) 2016-03-07 2017-09-14 Agrofresh Inc. Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops
KR102243775B1 (ko) * 2016-05-12 2021-04-22 아나코르 파마슈티칼스 인코포레이티드 옥사보롤 에스터 및 이의 용도
MX2020005464A (es) 2017-11-30 2020-12-03 Boragen Inc Compuestos de benzoxaborol y formulaciones de los mismos.
JP2020180170A (ja) * 2019-04-23 2020-11-05 東ソー株式会社 ハロゲン含有ポリエーテルポリオール組成物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
GB9411587D0 (en) 1994-06-09 1994-08-03 Zeneca Ltd Compound, composition and use
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
JO3396B1 (ar) 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
WO2010045503A1 (en) * 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
WO2010045505A1 (en) 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-protozoal agents
WO2011019618A1 (en) 2009-08-14 2011-02-17 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
ES2582471T3 (es) 2011-02-07 2016-09-13 Rempex Pharmaceuticals, Inc. Inhibidores polibásicos de la bomba de flujo de salida bacteriana que contienen boro y usos terapéuticos de los mismos
BR112014008186A2 (pt) 2011-10-07 2017-04-11 Syngenta Participations Ag método para proteção de plantas úteis ou material de propagação de plantas
AR088669A1 (es) 2011-11-21 2014-06-25 Lilly Co Eli Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos
US8669207B1 (en) * 2013-01-30 2014-03-11 Dow Agrosciences, Llc. Compounds and compositions
WO2015013318A1 (en) 2013-07-22 2015-01-29 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
CN105492388B (zh) 2013-08-09 2018-12-21 葛兰素史克知识产权第二有限公司 三环苯并氧杂硼杂环戊烯化合物及其用途
EP3086645A1 (en) 2013-12-23 2016-11-02 Syngenta Participations AG Benzoxaborole fungicides
US20180244699A1 (en) * 2015-08-17 2018-08-30 Syngenta Participations Ag 1-hydroxy-3h-2,1-benzoxaborole derivatives and their use as microbiocides
KR102243775B1 (ko) * 2016-05-12 2021-04-22 아나코르 파마슈티칼스 인코포레이티드 옥사보롤 에스터 및 이의 용도

Also Published As

Publication number Publication date
MX2018015410A (es) 2019-05-27
TWI629279B (zh) 2018-07-11
CL2018003187A1 (es) 2019-01-11
US20210101916A1 (en) 2021-04-08
DK3578562T3 (da) 2021-07-12
KR102231489B1 (ko) 2021-03-23
KR20190002695A (ko) 2019-01-08
PE20191077A1 (es) 2019-08-20
US20200017531A1 (en) 2020-01-16
US10882872B2 (en) 2021-01-05
HUE056320T2 (hu) 2022-02-28
JP2019081770A (ja) 2019-05-30
SG11201809237RA (en) 2018-11-29
ECSP18091065A (es) 2019-07-31
UA121354C2 (uk) 2020-05-12
US20170327519A1 (en) 2017-11-16
UY37236A (es) 2018-01-02
UY37980A (es) 2020-06-30
IL262453A (en) 2018-12-31
IL263161B (en) 2022-05-01
CN109153688A (zh) 2019-01-04
NZ746906A (en) 2020-06-26
AU2018264116B2 (en) 2020-03-12
PT3578562T (pt) 2021-08-05
MX2018013743A (es) 2019-05-02
CR20180560A (es) 2019-01-25
AU2017263785A1 (en) 2018-10-25
PE20190119A1 (es) 2019-01-17
TN2018000351A1 (en) 2020-06-15
TN2019000106A1 (en) 2020-10-05
EA036661B1 (ru) 2020-12-04
CA3023490A1 (en) 2017-11-16
BR122018076188A2 (pt) 2019-09-10
EP3455227A1 (en) 2019-03-20
CN109503637B (zh) 2021-03-16
HK1258717A1 (zh) 2019-11-15
CA3023490C (en) 2021-06-08
TW201808968A (zh) 2018-03-16
KR20190005982A (ko) 2019-01-16
NI201801171A (es) 2019-04-10
ECSP19026702A (es) 2019-06-30
CO2018012077A2 (es) 2018-11-22
MA44968A (fr) 2019-03-20
ES2882782T3 (es) 2021-12-02
CN109503637A (zh) 2019-03-22
WO2017195069A1 (en) 2017-11-16
US10562921B2 (en) 2020-02-18
AR108450A1 (es) 2018-08-22
AR113543A2 (es) 2020-05-13
CR20180502A (es) 2018-12-21
JP6715957B2 (ja) 2020-07-01
EP3578562A1 (en) 2019-12-11
JP2019520326A (ja) 2019-07-18
US11578087B2 (en) 2023-02-14
JP6715966B2 (ja) 2020-07-01
KR102243775B1 (ko) 2021-04-22
EP3578562B1 (en) 2021-06-23
BR122023022427A2 (pt) 2023-12-26
AU2017263785B2 (en) 2019-10-03
NI201801172A (es) 2019-04-10
AU2018264116A1 (en) 2018-12-06
CL2018003377A1 (es) 2019-01-11
IL263161A (en) 2018-12-31
BR112018071931A2 (pt) 2019-02-05
UA120999C2 (uk) 2020-03-10
EA034415B1 (ru) 2020-02-05
EA201892203A1 (ru) 2019-04-30
US20230132298A1 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
EA201990912A1 (ru) Анти-lag-3 антитела и их композиции
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
EA201891202A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891201A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
EA201890050A1 (ru) Композиции, содержащие бактериальные штаммы
EA201791867A1 (ru) Бициклические гетероциклы как ингибиторы fgfr4
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891200A1 (ru) Композиции, содержащие бактериальные штаммы
EA202091898A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
EA201790413A1 (ru) Антитела против tigit
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201892475A1 (ru) Оксабороловые сложные эфиры, их применение
EA201890048A1 (ru) Композиции, содержащие бактериальные штаммы
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201892802A1 (ru) Производные аденозина для применения при лечении рака
CY1125150T1 (el) Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου
EA201692091A1 (ru) Хиноксалиновые соединения и их применение
EA201890810A1 (ru) Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM